Related Experiment Videos
[Immunosuppressive therapy in renal transplantation]
1Department of Urology, National Defense Medical College.
Summary
The evolution of immunosuppressive drugs, from early agents like azathioprine and steroids to newer options like cyclosporine A and OKT3, has improved patient survival but graft survival remains a challenge. Newer monoclonal antibodies show promise in managing rejection after renal transplantation.
Area of Science:
- Immunology
- Pharmacology
- Nephrology
Context:
- Early immunosuppressive therapy for renal transplantation relied on 6-mercaptopurine (6-MP) and corticosteroids.
- Azathioprine, a derivative of 6-MP, and corticosteroids formed the standard maintenance therapy for over two decades.
- These first-generation agents, while improving patient survival, contributed to significant complications and limited graft survival improvements.
Purpose:
- To review the historical development and impact of immunosuppressive medications in renal transplantation.
- To compare the efficacy and side-effect profiles of first-generation, second-generation, and newer immunosuppressive agents.
- To highlight the advancements in immunosuppression, including the role of monoclonal antibodies like OKT3.
Summary:
- First-generation immunosuppressants (azathioprine, steroids) caused complications and showed limited graft survival benefits.
- Second-generation agents like antilymphocyte globulin (ALG) and cyclosporine A offered improved specificity but had their own side effects, notably nephrotoxicity with cyclosporine A.
- Monoclonal antibodies, such as OKT3, target specific lymphocyte populations, demonstrating remarkable efficacy in reversing established rejection and reducing rejection frequency.
Impact:
- Improved understanding of the immunologic basis of transplant rejection.
- Development of more targeted and effective immunosuppressive therapies.
- Enhanced graft survival rates and patient outcomes in renal transplantation.
- Identification of critical drug interactions, particularly with cyclosporine A and urologic infection treatments.